53

Rucaparib

53 Publications Verification

Cat. No.: HY-10617A

CAS No.: 283173-50-2

Purity: 99.97%

Synonyms: AG014699; PF-01367338

Target:

PARP

Research Areas:

Cancer

Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

52

Rucaparib phosphate

52 Cited Publications

Cat. No.: HY-10617

CAS No.: 459868-92-9

Purity: 99.56%

Synonyms: AG-014699 phosphate; PF-01367338 phosphate

Target:

PARP

Research Areas:

Cancer

Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

43

Rucaparib monocamsylate

43 Cited Publications

Cat. No.: HY-102003

CAS No.: 1859053-21-6

Purity: 99.82%

Synonyms: AG014699 monocamsylate; PF-01367338 monocamsylate

Target:

PARP

Research Areas:

Cancer

Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

22

Tasquinimod

22 Cited Publications

Cat. No.: HY-10528

CAS No.: 254964-60-8

Purity: 99.94%

Synonyms: ABR-215050

Target:

HDAC

Research Areas:

Cancer

Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

21

CC-885

21 Cited Publications

Cat. No.: HY-101488

CAS No.: 1010100-07-8

Purity: 99.85%

Target:

Molecular Glues Ligands for E3 Ligase Eukaryotic Release Factor (eRF) Apoptosis

Research Areas:

Neurological Disease Cancer

CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a K_d of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

16

AU-15330

16 Cited Publications

Cat. No.: HY-145388

CAS No.: 2380274-50-8

Purity: 99.89%

Target:

PROTACs SWI/SNF Complex

Research Areas:

Cancer

AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity .

Compare

loading...